Refractory Epilepsy: Clinical Trials

5 trials for Refractory Epilepsy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 unknown, 1 withdrawn. 5 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 23Completed 2, Withdrawn 1

Follow Refractory Epilepsy: new trials by email Literature Review of Refractory Epilepsy trials Research Report on Refractory Epilepsy

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy
Phase 3RecruitingUMC Utrecht502025-02-062026-06-25
Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
Traditional Treatment (Group T), Ketamine Infusion (Group K) - Refractory Epilepsy
Phase 2 / Phase 3WithdrawnUniversity of Alabama at Birmingham2017-05-042021-05-21
Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy
Modified Atkin Diet - Refractory Epilepsy
Phase 2 / Phase 3CompletedLady Hardinge Medical College312012-11-012019-01-15
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
Simplified Modified Atkins Diet, Antiepileptic drugs alone - Refractory Epilepsy
Phase 2 / Phase 3CompletedLady Hardinge Medical College812012-09-012019-01-15
Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy
Low glycemic index diet, Control group - Refractory Epilepsy
Phase 3UnknownAll India Institute of Medical Sciences402011-06-012012-07-20

Narrower conditions

Drug Resistant Epilepsy (5)  ·  Epilepsy (1)  ·  Rare Diseases (1)  ·  Seizures (1)

Broader conditions

Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Nervous System Diseases (5)  ·  Epilepsy (4)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Disease Attributes (1)  ·  Neurologic Manifestations (1)  ·  Pathologic Processes (1)  ·  Signs and Symptoms (1)

Interventions

Anticonvulsants (1)  ·  Barbiturates (1)  ·  Benzodiazepines (1)  ·  Cannabidiol (1)  ·  Control Groups (1)  ·  Ketamine (1)  ·  Propofol (1)  ·  Sensitivity Training Groups (1)

Sponsors

Lady Hardinge Medical College (2)  ·  All India Institute of Medical Sciences (1)  ·  UMC Utrecht (1)  ·  University of Alabama at Birmingham (1)

Countries

India (3)  ·  Netherlands (1)  ·  United States (1)

Top investigators

Satinder Aneja, MD (2)  ·  Sheffali Gulati, MD (1)  ·  Vinodkumar Singh, MD (1)

Results publications

PMID 30232735, PMID 32588435

NIH funding

2023 (1)